Condition
Multiple Myeloma With Failed Remission
Total Trials
5
Recruiting
0
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Active Not Recruiting3
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04184050Phase 1Active Not Recruiting
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT05673083Active Not Recruiting
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT03428373Phase 2Active Not Recruiting
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
NCT03650491Phase 1Completed
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT03687125Phase 1Terminated
Tinostamustine Conditioning and Autologous Stem Cell
Showing all 5 trials